

Literaturverzeichnis Aul/Giagounidis 2004-2007

[Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R.](#)

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.

Haematologica. 2006 Dec;91(12):1596-604.

[Giagounidis AA, Haase S, Heinsch M, Gohring G, Schlegelberger B, Aul C.](#)

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.

Ann Hematol. 2007 Feb;86(2):133-7. Epub 2006 Nov 17.

[Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S, Campbell LJ, Wang L, Langford CF, Fidler C, Oscier D, Aul C, Wainscoat JS, Boulwood J.](#)

Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

Blood. 2006 Jul 1;108(1):337-45. Epub 2006 Mar 9.

[Germing U, Strupp C, Kuendgen A, Aivado M, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N.](#)

Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.

Br J Haematol. 2006 Jan;132(2):162-7. Erratum in: Br J Haematol. 2006 Jul;134(2):247.

[Giagounidis AA, Germing U, Aul C.](#)

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.

Clin Cancer Res. 2006 Jan 1;12(1):5-10. Review.

[Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, Lubbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kundgen A, Mueller T, Haas R, Gattermann N, Aul C.](#)

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).

Leukemia. 2005 Dec;19(12):2223-31.

[Aul C, Giagounidis A, Heinsch M, Germing U, Ganser A.](#)

Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.

Rev Clin Exp Hematol. 2004 Dec 1;8(2):E1. Review.

[Giagounidis AA, Heinsch M, von Barany RU, Erlemannb R, Aul C.](#)

Breast cancer metastasis to the aortic vessel wall.

Onkologie. 2005 Jun;28(6-7):369.

[Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C.](#)

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.

Ann Hematol. 2005 Sep;84(9):569-71. Epub 2005 May 13.

[Giagounidis AA, Haase S, Germing U, Heinsch M, Aul C.](#)

Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion.

Acta Haematol. 2005;113(2):146-9.

[Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Busche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lubbert M, Ganser A, Aivado M, Heinsch M, Aul C.](#)

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.

Ann Hematol. 2005 Jun;84(6):389-94. Epub 2005 Mar 23.

[Giagounidis AA, Germing U, Wainscoat JS, Boulton J, Aul C.](#)

The 5q- syndrome.

Hematology. 2004 Aug;9(4):271-7.

[Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C, Loffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Balleisen L, Gruneisen A, Aul C, Lengfelder E, Hehlmann R, Kern W, Serve HL, Mesters RM, Eimermacher H, Frickhofen N, Kienast J, Giagounidis A, Sauerland MC, Heinecke A; German AMLCG.](#)

Subgroup specific therapy effects in AML: AMLCG data.

Ann Hematol. 2004;83 Suppl 1:S100-1.